How can stem cell costs be made more affordable?

Question

Accepted Answer

Making Stem Cell Costs More Affordable

iPS Portal Inc. aims to reduce the cost of its induced pluripotent stem cell (iPS cell) storage service by increasing the volume of orders over time, ultimately making the service affordable for everyone. The company projects that an increase in order volume will lead to a decrease in the per-unit cost of cell production and related processes. Initially, the cost for generating and storing a patient's own iPS cells is estimated to range from 10 million yen (approximately RM247,125.79) to 20 million yen (approximately RM296,550.95).
Increasing Order Volume to Drive Down Costs

The core strategy iPS Portal Inc. plans to employ to make its iPS cell storage service more affordable is to scale up its operations through a gradual increase in the number of orders received. The company has set a target of securing orders from 20 individuals in the service's inaugural year. By projecting a growth in demand over subsequent years, iPS Portal anticipates achieving economies of scale. This increase in volume is expected to directly impact the initial high costs associated with cell production and the associated complex processes, thereby lowering the overall expense for future clients.
High Initial Investment in Cell Production

The significant initial cost of generating and storing iPS cells is a substantial barrier to accessibility. The estimated expense for these procedures, including cell production and related processes, falls between 10 million yen (US$63,000) and 20 million yen. This high upfront investment reflects the intricate nature of iPS cell technology, which involves specialised laboratory work and stringent quality control measures to ensure the safety and efficacy of the cells for potential future clinical applications.
Establishing Quality Standards for Future Use

While the prospect of using a patient's own iPS cells offers the advantage of potentially preventing immune rejection, the field currently faces challenges such as the absence of unified quality standards for these cells. iPS Portal Inc., in collaboration with pharmaceutical experts, has established its own rigorous quality standards. This focus on quality is essential for ensuring that the manufactured and stored cells meet the necessary criteria for future clinical use, as highlighted by Junya Toguchida, assistant director at Kyoto University’s Centre for iPS Cell Research and Application and managing director of iPS Portal, who stressed the importance of confirming the characteristics and safety of each individual's cells.

Reading history

Hide →

This history is cleared when the page is closed.

How can stem cell costs be made more affordable?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends